Last reviewed · How we verify
Tobramycin 0.3% - Dexamethasone 0.1%
At a glance
| Generic name | Tobramycin 0.3% - Dexamethasone 0.1% |
|---|---|
| Sponsor | Veroia General Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (PHASE4)
- Effect of Bromfenac on Pain Related to Pterygium Surgery (PHASE4)
- Bevacizumab Injection for Recurrent Pterygium
- A Bioequivalence Study to Compare the Pharmacokinetics (PK) Of Marketed Product TobraDex® To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin And Dexamethasone In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery (PHASE3)
- Ketorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery (NA)
- Efficacy Comparison Study of Steroids to Control Post-operative Inflammation (PHASE4)
- A Bioequivalence Study of Tobradex AF (PHASE3)
- Zylet vs TobraDex in Blepharokeratoconjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tobramycin 0.3% - Dexamethasone 0.1% CI brief — competitive landscape report
- Tobramycin 0.3% - Dexamethasone 0.1% updates RSS · CI watch RSS
- Veroia General Hospital portfolio CI